Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4 (2017)
- Authors:
- USP affiliated author: HEGG, ROBERTO - FM
- School: FM
- Subjects: NEOPLASIAS MAMÁRIAS; PROGNÓSTICO; SOBREVIVÊNCIA LIVRE DE DOENÇA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título do periódico: Annals of oncology
- ISSN: 0923-7534
- Volume/Número/Paginação/Ano: v. 28, suppl.5, 2017
- Conference title: 42nd European-Society-for-Medical-Oncology Congress (ESMO)
-
ABNT
BACHELOT, T et al. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. . Acesso em: 07 jul. 2022. , 2017 -
APA
Bachelot, T., Royce, M., Villanueva, C., Cruz, F. M., Hegg, R., Falkson, C., et al. (2017). Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. Oxford: Faculdade de Medicina, Universidade de São Paulo. -
NLM
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. 2017 ; 28[citado 2022 jul. 07 ] -
Vancouver
Bachelot T, Royce M, Villanueva C, Cruz FM, Hegg R, Falkson C, Jeong J, Srimuninnimit V, Arce CH, Ridolfi A. Everolimus (EVE) plus letrozole (LET) in patients (pts) with estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Progression-free survival (PFS) subgroup analyses in BOLERO-4. Annals of oncology. 2017 ; 28[citado 2022 jul. 07 ] - Galactorreia: sindrome hiperprolactinemica
- Como diagnosticar e tratar sindrome do climaterio
- Hormonioterapia de reposicao e cancer de mama
- Prevencao da osteoporose
- Câncer de mama
- Recursos terapêuticos na doente terminal
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial
- Fatores prognósticos do câncer genital
- Evaluation the predictive value of biomarkers for efficacy outcomes in response to pertuzumab and trastuzumab based therapy: An exploratory analysis of the tryphaena study
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
